Global R&D Pipeline
My Favorite
Hot Targets:
CD33
Back
Total number of drugs
149
Phase II and later clinical stages
0.7%
Involving companies
164
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPM-2 | SPM-2 | Trispecific killer cell engager (TriKE) | Neoplasms Hemic and Lymphatic Diseases | CD123 inhibitors CD33 inhibitors ADCC | SpectraLab Scientific, Inc. | University Hospital Tübingen | Preclinical | - | - | - | - | - | - | - | - | - | SPM-2 | - | - | detail > | |
| CIK-CAR.CD33(Formula Pharmaceuticals) | CIK-CAR.CD33(Formula Pharmaceuticals) | CAR-CIK | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors CIK cells replacements | Formula Pharmaceuticals, Inc. | Formula Pharmaceuticals, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CIK-CAR.CD33(Formula Pharmaceuticals) | - | - | detail > | |
| CD33 editing HSPC(Columbia University) | CD33 editing HSPC(Columbia University) | Gene editing | Neoplasms Hemic and Lymphatic Diseases | CD33 modulators | Columbia University | Columbia University | Preclinical | - | - | - | - | - | - | - | - | - | CD33 editing HSPC(Columbia University) | - | - | detail > | |
| AMG-330 | AMG-330 | Bispecific T-cell Engager (BiTE) | Neoplasms Hemic and Lymphatic Diseases | CD3 stimulants CD33 inhibitors ADCC | Amgen, Inc. | Ludwig-Maximilians-Universität München Amgen Research (Munich) GmbH | Preclinical | Pending (in Phase 1) | - | - | - | - | - | - | - | - | AMG-330 | - | - | detail > | |
| CD123/CD33-LP-DNR | CD123/CD33-LP-DNR | Drug conjugates | Neoplasms Hemic and Lymphatic Diseases | CD123 inhibitors CD33 inhibitors | Sichuan University | Sichuan University | Preclinical | - | - | - | - | - | - | - | - | - | CD123/CD33-LP-DNR | - | - | detail > | |
| CD33 Targeted CAR-NK(Goethe University) | CD33 Targeted CAR-NK(Goethe University) | CAR-NK | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors NKG2A antagonists | Johann Wolfgang Goethe-Universität Frankfurt am Main Miltenyi Biotec, Inc. | Miltenyi Biotec, Inc. Johann Wolfgang Goethe-Universität Frankfurt am Main Miltenyi Biotec BV & Co. KG Lentigen Technology, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD33 Targeted CAR-NK(Goethe University) | - | - | detail > | |
| ATLX-1088 | ATLX-1088 | Monoclonal antibody | Nervous System Diseases | CD33 inhibitors | Alchemab Therapeutics Ltd. | Alchemab Therapeutics Ltd. | Preclinical | - | - | - | - | - | - | - | - | - | ATLX-1088 | - | - | detail > | |
| IBR-733 | IBR-733 | CAR-NK | Neoplasms Hemic and Lymphatic Diseases | CD33 modulators CLL-1 modulators Natural killer cell replacements | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Imbioray (Hangzhou) Biomedicine Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | IBR-733 | - | - | detail > | |
| BL-M11D1 | BL-M11D1 | Antibody drug conjugate (ADC) | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors TOP1 inhibitors | Sichuan Baili Pharmaceuticals Co.,Ltd | Sichuan Baili Pharmaceuticals Co.,Ltd Systimmune, Inc. | Phase 1 | Phase 1 | - | - | - | - | - | Cleavable linker | Ed-04 | - | BL-M11D1 | - | - | detail > | |
| Anti-CD33 CAR-T (Beijing Gaobo Boren Hospital ) | Anti-CD33 CAR-T (Beijing Gaobo Boren Hospital ) | Autologous CAR-T | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors | Beijing Gaobo Boren Hospital Co., Ltd. | Beijing Gaobo Boren Hospital Co., Ltd. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | Anti-CD33 CAR-T (Beijing Gaobo Boren Hospital ) | - | - | detail > |
Total 149 data
1
2
3
4
5
6
...
14
15
